Protective effects of PPARγ agonist in acute nephrotic syndrome

Nephrology Dialysis Transplantation

Volumn 27, Issue 1, 2012, Pages 174-181

  Zuo, Yiqin ^a   Yang, Hai Chun ^a   Potthoff, Sebastian A ^a,b   Najafian, Behzad ^a,c   Kon, Valentina ^a   Ma, Li Jun ^a   Fogo, Agnes B ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

nephrotic syndrome; podocytes; PPAR ; puromycin aminonucleoside

Indexed keywords

ALBUMIN; ALPHA ACTININ 4; AQUAPORIN 2; DESMIN; EPITHELIAL SODIUM CHANNEL; EPITHELIAL SODIUM CHANNEL GAMMA; MESSENGER RNA; NEPHRIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; PROTEIN KINASE B; PUROMYCIN AMINONUCLEOSIDE; SYNAPTOPODIN; UNCLASSIFIED DRUG;

ALBUMIN BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL DAMAGE; CELL FUNCTION; CELL STRUCTURE; CELL SURVIVAL; CONTROLLED STUDY; DRUG EFFECT; ENZYME PHOSPHORYLATION; FLUID BALANCE; FRACTIONAL POTASSIUM EXCRETION; FRACTIONAL SODIUM EXCRETION; GENE EXPRESSION REGULATION; GLOMERULUS FILTRATION; IN VITRO STUDY; IN VIVO STUDY; MALE; NEPHROTIC SYNDROME; NONHUMAN; PODOCYTE; PODOCYTE FOOT PROCESS EFFACEMENT; POTASSIUM EXCRETION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEINURIA; RAT; SODIUM EXCRETION; UREA NITROGEN BLOOD LEVEL; URINE VOLUME;

ACTININ; ACUTE DISEASE; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; AQUAPORIN 2; BLOTTING, WESTERN; CELLS, CULTURED; DESMIN; EPITHELIAL SODIUM CHANNEL; HYPOGLYCEMIC AGENTS; IMMUNOENZYME TECHNIQUES; MALE; NEPHROTIC SYNDROME; PODOCYTES; PPAR GAMMA; PROTEINURIA; PUROMYCIN AMINONUCLEOSIDE; RATS; RATS, SPRAGUE-DAWLEY; THIAZOLIDINEDIONES; WATER-ELECTROLYTE BALANCE;

EID: 84863050539     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfr240     Document Type: Article

References (44)

1. Hammarstedt A, Andersson CX, Rotter Sopasakis V et al. The effect of PPARgamma ligands on the adipose tissue in insulin resistance. Prostaglandins Leukot Essent Fatty Acids 2005; 73: 65-75 (Pubitemid 40826930)
2. Wang M, Tafuri S. Modulation of PPARgamma activity with pharmaceutical agents: treatment of insulin resistance and atherosclerosis. J Cell Biochem 2003; 89: 38-47 (Pubitemid 36459096)
3. Jiang C, Ting AT, Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 1998; 391: 82-86 (Pubitemid 28079219)
4. Wick M, Hurteau G, Dessev C et al. Peroxisome proliferator-activated receptor-gamma is a target of nonsteroidal anti-inflammatory drugs mediating cyclooxygenase-independent inhibition of lung cancer cell growth. Mol Pharmacol 2002; 62: 1207-1214 (Pubitemid 35222513)
5. Kanjanabuch T, Ma LJ, Chen J et al. PPAR-gamma agonist protects podocytes from injury. Kidney Int 2007; 71: 1232-1239 (Pubitemid 46884258)
6. Yang HC, Deleuze S, Zuo Y et al. The PPARgamma agonist piogli-tazone ameliorates aging-related progressive renal injury. J Am Soc Nephrol 2009; 20: 2380-2388
7. Yang HC, Ma LJ, Ma J et al. Peroxisome proliferator-activated receptor-gamma agonist is protective in podocyte injury-associated sclerosis. Kidney Int 2006; 69: 1756-1764 (Pubitemid 43739202)
8. Yotsumoto T, Naitoh T, Kanaki T et al. A novel peroxisome prolif-erator-activated receptor (PPAR)gamma agonist, NIP-222, reduces urinary albumin excretion in streptozotocin-diabetic mice independent of PPARgamma activation. Metabolism 2003; 52: 1633-1637 (Pubitemid 38049285)
9. Kawai T, Masaki T, Doi S et al. PPAR-gamma agonist attenuates renal interstitial fibrosis and inflammation through reduction of TGF-beta. Lab Invest 2009; 89: 47-58
10. Venegas-Pont M, Sartori-Valinotti JC, Maric C et al. Rosiglitazone decreases blood pressure and renal injury in a female mouse model of systemic lupus erythematosus. Am J Physiol Regul Integr Comp Phys-iol 2009; 296: R1282-R1289
11. Bakris GL, Ruilope LM, McMorn SO et al. Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria. J Hypertens 2006; 24: 2047-2055 (Pubitemid 44371272)
12. Joy MS, Gipson DS, Dike M et al. Phase I trial of rosiglitazone in FSGS: I. Report of the FONT Study Group. Clin J Am Soc Nephrol 2009; 4: 39-47
13. Mao Z, Ong AC. Peroxisome proliferator-activated receptor gamma agonists in kidney disease-future promise, present fears. Nephron Clin Pract 2009; 112: c230-c241
14. Vasudevan AR, Balasubramanyam A. Thiazolidinediones: a review of their mechanisms of insulin sensitization, therapeutic potential, clinical efficacy, and tolerability. Diabetes Technol Ther 2004; 6: 850-863 (Pubitemid 40129333)
15. Guan Y, Hao C, Cha DR et al. Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption. Nat Med 2005; 11: 861-866 (Pubitemid 41161118)
16. Gardiner SM, Nunez DJ, Baer PG et al. Regional hemodynamic effects of the N-(2-benzoylphenyl)-L-tyrosine peroxisome proliferator-activated receptor-gamma ligand, GI 262570 [(S)-2-(2-benzoylphenylamino)-3-[4-[2-(5-methyl-2-phenyl-2- oxazol-4-yl)eth oxy]phenyl]propionic acid], in conscious rats. J Pharmacol Exp Ther 2004; 310: 1226-1233 (Pubitemid 39108945)
17. Niemeyer NV, Janney LM. Thiazolidinedione-induced edema. Phar-macotherapy 2002; 22: 924-929 (Pubitemid 34743442)
18. Arima S, Kohagura K, Takeuchi K et al. Biphasic vasodilator action of troglitazone on the renal microcirculation. J Am Soc Nephrol 2002; 13: 342-349 (Pubitemid 34106275)
19. Chen L, Yang B, McNulty JA et al. GI262570, a peroxisome prolif-erator-activated receptor {gamma} agonist, changes electrolytes and water reabsorption from the distal nephron in rats. J Pharmacol Exp Ther 2005; 312: 718-725 (Pubitemid 40189571)
20. Nofziger C, Chen L, Shane MA et al. PPARgamma agonists do not directly enhance basal or insulin-stimulated Na(1) transport via the epithelial Na(1) channel. Pflugers Arch 2005; 451: 445-453 (Pubitemid 41719576)
21. Gherardi E, Messori M, Rozzi R et al. Experimental nephrotic syndrome in the rat induced by puromycin aminonucleoside: hepatic synthesis of lipoproteins and apolipoproteins. Lipids 1980; 15: 858-863 (Pubitemid 11204490)
22. Guan N, Ding J, Deng J et al. Key molecular events in puromycin aminonucleoside nephrosis rats. Pathol Int 2004; 54: 703-711 (Pubitemid 39297296)
23. Lowenborg EK, Jaremko G, Berg UB. Glomerular function and morphology in puromycin aminonucleoside nephropathy in rats. Nephrol Dial Transplant 2000; 15: 1547-1555
24. Tojo A, Onozato ML, Kitiyakara C et al. Glomerular albumin filtration through podocyte cell body in puromycin aminonucleoside nephrotic rat. Med Mol Morphol 2008; 41: 92-98 (Pubitemid 351915432)
25. Yatsu T, Aoki M, Tanaka A. Effect of zelandopam, a dopamine D1-like receptor agonist, in puromycin aminonucleoside nephrosis rats. Eur J Pharmacol 2005; 510: 121-126 (Pubitemid 40312397)
26. Zheng CX, Chen ZH, Zeng CH et al. Triptolide protects podocytes from puromycin aminonucleoside induced injury in vivo and in vitro. Kidney Int 2008; 74: 596-612
27. Xu Q, Qaum T, Adamis AP. Sensitive blood-retinal barrier breakdown quantitation using Evans blue. Invest Ophthalmol Vis Sci 2001; 42: 789-794 (Pubitemid 32206923)
28. Sotiropoulos KB, Clermont A, Yasuda Y et al. Adipose-specific effect of rosiglitazone on vascular permeability and protein kinase C activation: novel mechanism for PPARgamma agonist's effects on edema and weight gain. FASEB J 2006; 20: 1203-1205
29. Vallon V, Hummler E, Rieg T et al. Thiazolidinedione-induced fluid retention is independent of collecting duct alphaENaC activity. J Am Soc Nephrol 2009; 20: 721-729
30. Toyoda M, Najafian B, Kim Y et al. Podocyte detachment and reduced glomerular capillary endothelial fenestration in human type 1 diabetic nephropathy. Diabetes 2007; 56: 2155-2160 (Pubitemid 47195834)
31. Liang XB, Ma LJ, Naito T et al. Angiotensin type 1 receptor blocker restores podocyte potential to promote glomerular endothelial cell growth. J Am Soc Nephrol 2006; 17: 1886-1895 (Pubitemid 44036173)
32. Takemoto M, Asker N, Gerhardt H et al. A new method for large scale isolation of kidney glomeruli from mice. Am J Pathol 2002; 161: 799-805 (Pubitemid 34988366)
33. Potthoff SA, Sitek B, Stegbauer J et al. The glomerular proteome in a model of chronic kidney disease. Proteomics 2008; 2: 1127-1139
34. Tiwari S, Blasi ER, Heyen JR et al. Time course of AQP-2 and ENaC regulation in the kidney in response to PPAR agonists associated with marked edema in rats. Pharmacol Res 2008; 57: 383-392
35. Nesto RW, Bell D, Bonow RO et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Circulation 2003; 108: 2941-2948 (Pubitemid 37517824)
36. Tang WH, Francis GS, Hoogwerf BJ et al. Fluid retention after initiation of thiazolidinedione therapy in diabetic patients with established chronic heart failure. J Am Coll Cardiol 2003; 41: 1394-1398 (Pubitemid 36439002)
37. Kiryluk K, Isom R. Thiazolidinediones and fluid retention. Kidney Int 2007; 72: 762-768 (Pubitemid 47373795)
38. Song J, Knepper MA, Hu X et al. Rosiglitazone activates renal sodium-and water-reabsorptive pathways and lowers blood pressure in normal rats. J Pharmacol Exp Ther 2004; 308: 426-433 (Pubitemid 38134200)
39. Kim SW, Wang W, Nielsen J et al. Increased expression and apical targeting of renal ENaC subunits in puromycin aminonucleoside-induced nephrotic syndrome in rats. Am J Physiol Renal Physiol 2004; 286: F922-F935 (Pubitemid 38508993)
40. Mundel P, Reiser J. Proteinuria: an enzymatic disease of the podo-cyte? Kidney Int 2010; 77: 571-580
41. Oh J, Reiser J, Mundel P. Dynamic (re)organization of the podocyte actin cytoskeleton in the nephrotic syndrome. Pediatr Nephrol 2004; 19: 130-137 (Pubitemid 38181002)
42. Shankland SJ. The podocyte's response to injury: role in proteinuria and glomerulosclerosis. Kidney Int 2006; 69: 2131-2147 (Pubitemid 43882099)
43. Ly J, Alexander M, Quaggin SE. A podocentric view of nephrology. Curr Opin Nephrol Hypertens 2004; 13: 299-305 (Pubitemid 38584614)
44. Benigni A, Zoja C, Tomasoni S et al. Transcriptional regulation of nephrin gene by peroxisome proliferator-activated receptor-gamma agonist: molecular mechanism of the antiproteinuric effect of piogli-tazone. J Am Soc Nephrol 2006; 17: 1624-1632 (Pubitemid 43794665)